US Pharma MarketingApnimed scouts $160m IPO to back late-stage sleep apnoea pill development
Apnimed will use the IPO funds to progress lead candidate oxnimbi, which could become the first pill to break onto the OSA market.
Apnimed will use the IPO funds to progress lead candidate oxnimbi, which could become the first pill to break onto the OSA market.
Source: Pharmaceutical Technology